These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 35022752)
1. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y J Antimicrob Chemother; 2022 Mar; 77(4):869-879. PubMed ID: 35022752 [TBL] [Abstract][Full Text] [Related]
2. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis. Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days. Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110 [TBL] [Abstract][Full Text] [Related]
4. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients. Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903 [TBL] [Abstract][Full Text] [Related]
6. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction. Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654 [TBL] [Abstract][Full Text] [Related]
7. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T; Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314 [TBL] [Abstract][Full Text] [Related]
8. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies. Wang YW; Hou HA; Lin CC; Lin HY; Chen PZ; Kuo CH; Chiu HH; Chuang CC; Chen YJ; Lin SW Adv Ther; 2024 Jul; 41(7):2966-2977. PubMed ID: 38743241 [TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections. Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens. Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731 [TBL] [Abstract][Full Text] [Related]
11. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate. Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Ide T; Takeda K; Nishi S; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T J Infect Chemother; 2022 Feb; 28(2):232-237. PubMed ID: 34844858 [TBL] [Abstract][Full Text] [Related]
12. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Okada K; Kimura T; Mikamo H; Kasahara K; Seki M; Takakura S; Tokimatsu I; Ohmagari N; Takahashi Y; Matsumoto K; Igarashi M; Kobayashi M; Hamada Y; Mochizuki T; Kimura M; Nishi Y; Tanigawara Y; Takesue Y; ; J Infect Chemother; 2014 Jan; 20(1):1-5. PubMed ID: 24486168 [TBL] [Abstract][Full Text] [Related]
13. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy. Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153 [TBL] [Abstract][Full Text] [Related]
14. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance. Hu S; Wang T; You H; Chen S; Zhang T; Dong Y J Clin Pharm Ther; 2022 Oct; 47(10):1548-1555. PubMed ID: 35633105 [TBL] [Abstract][Full Text] [Related]
15. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256 [TBL] [Abstract][Full Text] [Related]
16. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Matsumoto K; Oda K; Shoji K; Hanai Y; Takahashi Y; Fujii S; Hamada Y; Kimura T; Mayumi T; Ueda T; Nakajima K; Takesue Y Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335866 [TBL] [Abstract][Full Text] [Related]
17. Optimal Use and Need for Therapeutic Drug Monitoring of Teicoplanin in Children: A Systematic Review. Choi JS; Yoon SH; Park HJ; Lee SY; Kim YJ J Korean Med Sci; 2023 Feb; 38(7):e62. PubMed ID: 36808548 [TBL] [Abstract][Full Text] [Related]
18. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? Pea F; Cojutti PG; Baraldo M Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737 [TBL] [Abstract][Full Text] [Related]
19. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations. Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433 [TBL] [Abstract][Full Text] [Related]
20. Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. Pea F J Infect Chemother; 2020 Sep; 26(9):900-907. PubMed ID: 32624339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]